Combining angiotensin II blockade and renin receptor inhibition results in enhanced antifibrotic effect in experimental nephritis

American Journal of Physiology - Renal Physiology

Volumn 301, Issue 4, 2011, Pages

  Zhang, Jiandong ^a   Gu, Chunyan ^a   Noble, Nancy A ^a   Border, Wayne A ^a   Huang, Yufeng ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Enalapril; Fibrosis; TGF

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ENALAPRILAT; FIBRONECTIN; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTOR; RECEPTOR BLOCKING AGENT; RENIN RECEPTOR; RENIN RECEPTOR INHIBITOR; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ACUTE GLOMERULONEPHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFIBROTIC EFFECT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; EXTRACELLULAR MATRIX; GENE EXPRESSION; KIDNEY FIBROSIS; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RAT; RECEPTOR BLOCKING;

EID: 80053344229     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00271.2011     Document Type: Article

References (49)

1. Azizi M, Bissery A, Lamarre-Cliche M, Menard J. Integrating drug pharmacokinetics for phenotyping individual renin response to angiotensin II blockade in humans. Hypertension 43: 785-790, 2004.
2. Bantounas I, Phylactou LA, Uney JB. RNA interference and the use of small interfering RNA to study gene function in mammalian systems. J Mol Endocrinol 33: 545-557, 2004.
3. Batenburg WW, de Bruin RJ, van Gool JM, Müller DN, Bader M, Nguyen G, Danser AH. Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 28: 1151-1157, 2008.
4. Batenburg WW, Krop M, Garrelds IM, de Vries R, de Bruin RJ, Burckle CA, Muller DN, Bader M, Nguyen G, Danser AH. Prorenin is the endogenous agonist of the (pro)renin receptor. Binding kinetics of renin and prorenin in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor. J Hypertens 25: 2441-2453, 2007.
5. Biswas KBNA, Arai Y, Nakagawa T, Ebihara A, Ichihara A, Watanabe T, Inagami T, Suzuki F. Aliskiren binds to renin and prorenin bound to (pro)renin receptor in vitro. Hypertens Res 33: 1053-1059, 2010.
6. Border WA, Noble NA. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension 31: 181-188, 1998.
7. Border WA, Noble NA. Maximizing hemodynamic-independent effects of angiotensin II antagonists in fibrotic diseases. Semi Nephrol 21: 563-572, 2001.
8. Burckle CA, Jan Danser AH, Muller DN, Garrelds IM, Gasc JM, Popova E, Plehm R, Peters J, Bader M, Nguyen G. Elevated blood pressure and heart rate in human renin receptor transgenic rats. Hypertension 47: 552-556, 2006.
9. Chatziantoniou CDJ, Arendshorst WJ, Ardaillou R. Angiotensin II receptors and renin release in rat glomerular afferent arterioles. Kidney Int 46: 1570-1573, 1994.
10. Cheng HF, Wang SW, Zhang MZ, McKanna JA, Breyer R, Harris RC. Prostaglandins that increase renin production in response to ACE inhibition are not derived from cyclooxygenase-1. Am J Physiol Regul Integr Comp Physiol 283: R638-R646, 2002.
11. Doulton TW. ACE inhibitor-angiotensin receptor blocker combinations: a clinician's perspective. Mini Rev Med Chem 6: 491-497, 2006.
12. Esposito CPB, De Mauri A, Cornacchia F, Fasoli G, Foschi A, Mazzullo T, Plati A, Scudellaro R, Dal Canton A. Hepatocyte growth factor (HGF) modulates matrix turnover in human glomeruli. Kidney Int 67: 2143-2150, 2005.
13. Feldt S, Batenburg WW, Mazak I, Maschke U, Wellner M, Kvakan H, Dechend R, Fiebeler A, Burckle C, Contrepas A, Jan Danser AH, Bader M, Nguyen G, Luft FC, Muller DN. Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension 51: 682-688, 2008.
14. Feldt S, Batenburg WW, Mazak I, Maschke U, Wellner M, Kvakan H, Dechend R, Fiebeler A, Burckle C, Contrepas A, Jan Danser AH, Bader M, Nguyen G, Luft FC, Muller DN. Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension 51: 682-688, 2008.
15. Gaedeke J, Peters H, Noble NA, Border WA. Angiotensin II, TGF-β and renal fibrosis. Contrib Nephrol 135: 153-160, 2001.
16. Gomez RA, Chevalier RL, Everett AD, Elwood JP, Peach MJ, Lynch KR, Carey RM. Recruitment of renin gene-expressing cells in adult rat kidneys. Am J Physiol Renal Fluid Electrolyte Physiol 259: F660-F665, 1990.
17. Hano TSM, Baba A, Nishio I, Masuyama Y. DA1 receptor-mediated renin release from isolated rat glomeruli. Hypertens Res 18: 41-43, 1995.
18. Hayakawa KMY, Hiramatsu N, Kasai A, Yao J, Kitamura M. Spontaneous activation of the NF- B signaling pathway in isolated normal glomeruli. Am J Physiol Renal Physiol 291: F1169-F1176, 2006.
19. Hede K. Blocking cancer with RNA interference moves toward the clinic. J Natl Cancer Inst 97: 626-628, 2005.
20. Holdsworth SRTN, Glasgow EF, Dowling JP, Atkins RC. Tissue culture of isolated glomeruli in experimental crescentic glomerulonephritis. J Exp Med 147: 98-109, 1978.
21. Huang Y, Border WA, Yu L, Zhang J, Lawrence DA, Noble NA. A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy. J Am Soc Nephrol 19: 329-338, 2008.
22. Huang Y, Haraguchi M, Lawrence DA, Border WA, Yu L, Noble NA. A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J Clin Invest 112: 379-388, 2003.
23. Huang Y, Noble NA, Zhang J, Xu C, Border WA. Renin-stimulated TGF-beta1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. Kidney Int 72: 45-52, 2007.
24. Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L, Noble NA, Border W. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 69: 105-113, 2006.
25. Ichihara A, Hayashi M, Kaneshiro Y, Suzuki F, Nakagawa T, Tada Y, Koura Y, Nishiyama A, Okada H, Uddin MN, Nabi AH, Ishida Y, Inagami T, Saruta T. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J Clin Invest 114: 1128-1135, 2004.
26. Jefferson JA, Johnson RJ. Experimental mesangial proliferative glomerulonephritis (the anti-Thy-1.1 model). J Nephrol 12: 297-307, 1999.
27. Johns WD, Peach MJ, Gomez RA, Inagami T, Carey RM. Angiotensin II regulates renin gene expression. Am J Physiol Renal Fluid Electrolyte Physiol 259: F882-F887, 1990.
28. Kang YS, Lee MH, Song HK, Hyun YY, Cha JJ, Ko GJ, Kim SH, Lee JE, Han JY, Cha DR. Aliskiren improves insulin resistance and ameliorates diabetic vascular complications in db/db mice. Nephrol Dial Transplant 26: 1194-1204, 2011.
29. Karczewska JML, Dzierzko G, Stepiński J, Angielski S. The relationship between constitutive ATP release and its extracellular metabolism in isolated rat kidney glomeruli. J Physiol Pharmacol 58: 321-333, 2007.
30. Kramer BK, Ritthaler T, Schweda F, Ittner KP, Scholz H, Riegger GA, Kurtz A. Effects of the angiotensin II type-1 receptor antagonist ZD7155 on angiotensin II-mediated regulation of renin secretion and renal renin gene expression, renal vasoconstriction, and blood pressure in rats. J Cardiovasc Pharmacol 31: 700-705, 1998.
31. Kurtz A. Cellular control of renin secretion. Rev Physiol Biochem Pharmacol 113: 1-40, 1989.
32. Kurtz A, Wagner C. Regulation of renin secretion by angiotensin II-AT1 receptors. J Am Soc Nephrol 10, Suppl 11: S162-S168, 1999.
33. Leung RK, Whittaker PA. RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol Ther 107: 222-239, 2005.
34. Kitamura M. TGF-beta1 as an endogenous defender against macrophagetriggered stromelysin gene expression in the glomerulus. J Immunol 160: 5163-5168, 1998.
35. Melnyk RA, Tam J, Boie Y, Kennedy BP, Percival MD. Renin and prorenin activate pathways implicated in organ damage in human mesangial cells independent of angiotensin II production. Am J Nephrol 30: 232-243, 2009.
36. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 109: 1417-1427, 2002.
37. Okuda S, Languino LR, Ruoslahti E, Border WA. Elevated expression of transforming growth factor-β and proteoglycan production in experimental glomerulonephritis. J Clin Invest 86: 453-462, 1990.
38. Oparil SYS, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 370: 221-229, 2007.
39. Peters H, Border WA, Noble NA. Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 54: 1570-1580, 1998.
40. Pilz BSE, Wellner M, Fiebeler A, Dechend R, Gratze P, Meiners S, Feldman DL, Webb RL, Garrelds IM, Jan Danser AH, Luft FC, Müller DN. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 46: 569-579, 2005.
41. Rennard SI, Berg R, Martin GR, Foidart JM, Robey PG. Enzymelinked immunoassay (ELISA) for connective tissue components. Anal Biochem 104: 205-214, 1980.
42. Saris JJ, t Hoen PA, Garrelds IM, Dekkers DH, den Dunnen JT, Lamers JM, Jan Danser AH. Prorenin induces intracellular signaling in cardiomyocytes independently of angiotensin II. Hypertension 48: 564-571, 2006.
43. Schefe JH, Neumann C, Goebel M, Danser J, Kirsch S, Gust R, Kintscher U, Unger T, Funke-Kaiser H. Prorenin engages the (pro)renin receptor like renin and both ligand activities are unopposed by aliskiren. J Hypertens 26: 1787-1794, 2008.
44. Stanton AJC, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 42: 1137-1143, 2003.
45. Tomooka S, Border WA, Marshall BC, Noble NA. Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Int 42: 1462-1469, 1992.
46. Uraoka M, Ikeda K, Nakagawa Y, Koide M, Akakabe Y, Nakano- Kurimoto R, Takahashi T, Matoba S, Yamada H, Okigaki M, Matsubara H. Prorenin induces ERK activation in endothelial cells to enhance neovascularization independently of the renin-angiotensin system. Biochem Biophys Res Commun 390: 1202-1207, 2009.
47. Wagner C, Kurtz A. Effects of candesartan on the renin system in conscious rats. J Am Soc Nephrol 10, Suppl 11: S169-S171, 1999.
48. Yu L, Border WA, Anderson I, McCourt M, Huang Y, Noble NA. Combining TGF-β inhibition and Angiotensin II blockade results in enhanced anti-fibrotic effect. Kidney Int 66: 1774-1784, 2004.
49. Zhang J, Noble N, Border PW, Owens RT, Huang Y. Receptordependent prorenin activation and induction of PAI-1 expression in vascular smooth muscle cells. Am J Physiol Endocrinol Metab 295: E810-E819, 2008.